PDCD1 and melanoma: Antibodies targeting the PD-1–PD-L1/2 interaction have now been approved as first-line/second-line therapies for melanoma, lymphomas, lung cancers, bladder cancer, gastroesophageal cancer, head and neck squamous cell cancer, renal cell cancer, and liver cancer (1).